Home » INHIBITEX MOVES FORWARD WITH BLA FOR VERONATE
INHIBITEX MOVES FORWARD WITH BLA FOR VERONATE
Inhibitex has initiated the rolling submission of its biologics license
application (BLA) with the FDA for the use of Veronate to prevent hospital-associated
infections in infants weighing between 500 g and 1,250 g at birth.
The rolling submission is an FDA provision, available to drug candidates that
have received Fast Track designation, which allows for completed sections of
a BLA to be submitted on an ongoing basis.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May